How King is Executing On Its Strategy

King Pharmaceuticals® is achieving its vision through an enterprise-wide focus on its target, specialty driven markets, organic growth and a disciplined business development process.

King is taking a number of significant steps to better position the company for long-term growth and enhance shareholder value. Among the more significant steps: accelerating its plan to emphasize its neuroscience, hospital, and acute medicine platforms. Each of these represent specialty driven markets in which King has core capabilities and assets. Additionally, King has an existing strong presence and demonstrated commitment to meeting the needs of patients and physicians in these target markets.

To support the renewed focus on growth, King has aligned its organization and cost structure to effectively support its strategic priorities.

The company’s strategic plan is designed to achieve long-term value for its shareholders through organic growth and business development.

Organic growth

Maximizing the potential of currently marketed products. King has a strong portfolio of core marketed products. These products provide revenue and cash flow that enable King to invest in the future of the company through the continuing development of products in the company's pipeline and business development collaborations that add innovative products and technologies to King's portfolio of products in development.
Developing pipeline products through King’s R&D team: King’s 70-person strong in-house R&D team includes drug development scientists, regulatory and drug safety staff who manage the full range of R&D activities for late-stage products, including: drug discovery, clinical development, drug safety, regulatory affairs, medical affairs and project management. Additionally, King has established a highly cost-effective and efficient R&D model that sets it apart from other pharmaceutical companies.

Business development

Acquiring late stage compounds and developing partnerships for promising products and technologies. King has a highly-disciplined, best-in-class business development process. Through rigorous and focused screening, King is able to identify collaborations and products most aligned with the company’s strengths and strategy – to mutually benefit King, its business partners and the healthcare needs of the populations served. With a focus on late stage opportunities, King has completed several collaborations involving products in development. For example, King’s strategic alliance with Pain Therapeutics for Remoxy™, an abuse-deterrent version of long-acting oxycodone, that is now under evaluation in a Phase III clinical trial.
King’s renewed commitment to growth is also exemplified by the company’s recently announced licensing agreement with Acura Pharmaceuticals to develop and commercialize Acura’s Aversion® Technology, encompassing a wide-range of abuse-deterrent, immediate release optoid products. This agreement directly aligns with King’s emphasis on its neuroscience, hospital and acute medicine platforms, particularly King’s pain management franchise.
As a result of organic growth and partnering agreements, such as with Pain Therapeutics and Acura, King now has a solid foundation on which to develop a full complement of existing opioid compounds with demonstrated track records of efficacy to better address patient’s, physician’s and managed care’s needs by utilizing formulation technologies designed to offer effective pain relief while deterring common methods of abuse.
Expanding our markets. King also seeks to expand its markets into Canada and the European Union.

This page was last updated on 11/08/2007.